Influenza vaccination coverage and factors associated with severe laboratory-confirmed influenza-related illness in patients receiving care at a tertiary hospital in Catalonia (Spain) during the 2018-2019 epidemic season.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 22 11 2020
accepted: 09 11 2021
entrez: 2 12 2021
pubmed: 3 12 2021
medline: 6 1 2022
Statut: epublish

Résumé

Influenza vaccination rates in risk groups remain suboptimal. Evidence supporting a significant association between influenza vaccination and severe illness is limited. We retrospectively analyzed the epidemiological characteristics of out- and inpatients with laboratory-confirmed influenza infection attended during the 2018-19 epidemic season. Influenza vaccination coverage by indication was analyzed. Logistic regression was used to compare the odds of vaccination between severe and non-severe influenza-positive patients. Severe cases were defined as presenting pneumonia, admission to critical care units and/or death. The overall vaccination coverage among influenza-positive patients was 30.4%. In subjects with ≥ 1 indication for vaccination, the vaccination coverage was 42.4%. By indication, coverage rates were: 52.5% in patients aged ≥ 59 years, 42.2% in obese patients, 29.2% in immunosuppressed subjects and 6.5% in pregnant women. In patients with underlying chronic diseases, a higher coverage was found in patients with cognitive impairment (77%), muscular dystrophy (63.6%) and renal disease (60.4%). The multivariate logistic regression model showed severe influenza-related illness was associated with a lack of influenza vaccination before seeking care during the 2018-2019 season [0.59 (95%CI 0.36-0.97); p = 0.038], older age [1.01 (95%CI 1.00-1.02); p = 0.009] and current or former smoking status [1.63 (95%CI 0.84-3.18) and 2.03 (95%CI 1.16-3.57); p = 0.031], adjusted by underlying disease. Adjusting by age, smoking status and underlying disease, a moderate association between the influenza vaccine and severe laboratory-confirmed influenza-related illness was found in an epidemic season in which there was matching between the vaccine and circulating strains. Protection against complications, especially in older subjects and in those with underlying disease is postulated as one of the strengths of annual influenza vaccination. However, influenza vaccination is a pending issue in these groups, especially in pregnant women and obese people. To avoid suboptimal vaccination coverages, health professionals should recommend the seasonal influenza vaccination according to the annual instructions of the health authorities.

Identifiants

pubmed: 34855801
doi: 10.1371/journal.pone.0260397
pii: PONE-D-20-36736
pmc: PMC8638936
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0260397

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Sci Rep. 2019 Sep 6;9(1):12853
pubmed: 31492899
J Infect Dis. 2019 Sep 13;220(8):1265-1275
pubmed: 30561689
Emerg Infect Dis. 2020 Feb;26(2):220-228
pubmed: 31961295
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Euro Surveill. 2018 Oct;23(43):
pubmed: 30376915
Influenza Other Respir Viruses. 2017 Sep;11(5):372-393
pubmed: 28745014
J Intern Med. 2011 Mar;269(3):258-69
pubmed: 21175903
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Gac Sanit. 2021 Jul-Aug;35(4):339-344
pubmed: 32331814
PLoS Med. 2016 Mar 24;13(3):e1001977
pubmed: 27011229
Rev Esp Salud Publica. 2019 Apr 29;93:
pubmed: 31032821
Eur J Public Health. 2018 Feb 1;28(1):150-155
pubmed: 29020390
Med Clin (Barc). 2020 Aug 14;155(3):112-118
pubmed: 32423688
Vaccine. 2020 Feb 18;38(8):1925-1932
pubmed: 31982263
BMC Public Health. 2019 Aug 13;19(1):1089
pubmed: 31409397

Auteurs

Guillermo Mena (G)

Servicio de Medicina Preventiva, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Irma Casas (I)

Servicio de Medicina Preventiva, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Cristina Casañ (C)

Servicio de Microbiologia, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Mario Auñón (M)

Servicio de Medicina Preventiva, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Lurdes Matas (L)

Universitat Autònoma de Barcelona, Barcelona, Spain.
Servicio de Microbiologia, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
CIBER Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.

Josep-Maria Mòdol (JM)

Universitat Autònoma de Barcelona, Barcelona, Spain.
Dirección Médica, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

María Esteve (M)

Servicio de Medicina Preventiva, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH